Medtronic Announces Initiation of U.S. Pivotal Trial to Evaluate the Cardioblate(R) Surgical Ablation System to Treat Permanent Atrial Fibrillation.
Business Wire › March 15, 2007
Linked as:
Extract
Medtronic Announces Initiation of U.S. Pivotal Trial to Evaluate the Cardioblate(R) Surgical Ablation System to Treat Permanent Atrial Fibrillation.
MINNEAPOLIS -- Medtronic, Inc. (NYSE:MDT), announced today the start of the U.S. pivotal clinical trial for the Cardioblate[R] Surgical Ablation System to treat the cause of permanent atrial fibrillation (AF). The Medtronic Cardiob...
See the full content of this document
Sponsored links
